| Literature DB >> 28355888 |
Roberto Salvi1, Cristal Cerqueira-Coutinho2, Eduardo Ricci-Junior3, Sofia Nascimento Dos Santos4, Suyene Rocha Pinto4, Emerson Soares Bernardes5, Patricia Lopes Barros de Araujo6, Ralph Santos-Oliveira4.
Abstract
The diagnosis of lung cancer mostly occurs when the cancer is already in an advanced stage. In this situation, there are few options for the treatment and most of them have few chances of success. In this study, we developed and tested etoposide microparticles as a diagnostic agent for imaging lung cancer at early stages of development. We tested etoposide microparticles labeled with technetium 99m in inducted mice. The results demonstrated that over 10% of the total dose used was uptake by the tumor site. Also, the results showed that the microparticles had a good renal clearance and low uptake by liver and spleen. The data suggest that these micro-radiopharmaceuticals may be used for lung cancer imaging exam, especially single-photo emission computed tomography (SPECT).[Formula: see text].Entities:
Keywords: Radiopharmaceuticals; cancer; micro-radiopharmaceuticals; nuclear medicine; oncology
Mesh:
Substances:
Year: 2017 PMID: 28355888 DOI: 10.1080/21691401.2017.1307848
Source DB: PubMed Journal: Artif Cells Nanomed Biotechnol ISSN: 2169-1401 Impact factor: 5.678